GOLDEN, Colo.--(BUSINESS WIRE)--Vitro Diagnostics, Inc. (OTCBB: VODG), dba Vitro Biopharma, announced the introduction of “Tools for Stem Cell and Drug Development™” at the recently held Society of Toxicology meeting in Baltimore, MD. These products are designed to support stem cell and cancer research specifically targeting mesenchymal stem cells (MSCs) and a new type of stem cell called induced plurapotent stem cells (iPS). MSCs are adult stem cells that differentiate into several tissue-specific cells, such as collagen, bone and fat cells as well as others. Expanded usage of adult stem cells such as those provided by Vitro provides two major benefits. First, use of Vitro’s adult stem cells eliminates ethical and religious issues associated with embryonic stem cells. Secondly, the use of Vitro’s adult stem cells will enable use of personalized cells that should eliminate immune rejection of transplanted cells. Also, use of personalized stem cells may lead to a new era of regenerative medicine involving the banking of cells such as umbilical cord blood for later use to generate “designer” stem cells derived from the individual patient for treatment of degenerative disorders including diabetes, heart disease, Alzheimer’s disease as well as cancer and many other disorders.
